phrykt

Vaxart, Inc. (VXRT): who owns it and who trades it

As of Nov 5, 2026, VXRT insiders reported 5 purchases worth $30.6K in the last 12 months. The largest buyer was Elaine J Heron (Director), with $15.9K.

Latest filing Nov 5, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, VXRT insiders reported $30.6K of open-market purchases and $0 of sales.

Purchases, 12 months
$30.6K
5 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 22, 2026
Filed May 26, 2026

Purchases and sales by month

$6.5K$6.5KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 22, 2026W. Mark WatsonDirectorPurchase10,000$0.65$6.5KForm 4
Nov 17, 2025W. Mark WatsonDirectorPurchase15,000$0.41$6.2KForm 4
Nov 17, 2025W. Mark WatsonDirectorPurchase5,000$0.41$2KForm 4
Nov 17, 2025Elaine J HeronDirectorPurchase23,217$0.39$9.1KForm 4
Nov 17, 2025Elaine J HeronDirectorPurchase16,783$0.41$6.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Elaine J HeronDirector$15.9K–Nov 17, 2025
W. Mark WatsonDirector$14.7K–May 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VXRT short interest

Low short interest. 1.0% of VXRT shares are sold short: about 1 share in 101. Over the last 12 reports the number of shares short went down 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.42M VXRT shares were sold short, 1.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 611,586 shares, buying them all back would take about 4.0 trading days (days to cover).

Shares short, % of all shares

0.99%May 15Oct 301.13%

Days to cover

4.0May 15Oct 305.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.42M0.99%+1%611,5864.0
Oct 15, 20262.40M0.99%+3%495,2654.8
Sep 30, 20262.33M0.96%+1%499,8394.7
Sep 15, 20262.31M0.95%-0%517,6644.5
Aug 31, 20262.31M0.95%-1%602,6093.8
Aug 14, 20262.33M0.96%-5%432,8375.4
Jul 31, 20262.46M1.01%-4%627,2633.9
Jul 15, 20262.57M1.07%-1%603,7594.3
Jun 30, 20262.59M1.07%-2%750,2593.5
Jun 15, 20262.63M1.09%-1%625,5634.2
May 29, 20262.66M1.10%-0%946,0612.8
May 15, 20262.66M1.11%-9%962,8852.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vaxart company events

Vaxart filed 17 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026LeadershipFollowing a recommendation by the Nominating and Governance Committee of the Board of Directors of Vaxart, Inc., the Board appointed Raquel C. Bono, M.D., M.B.A., FACS, to serve on the Board, effective immediately, and until Dr. Bono’s successor is elected and qualified, or sooner in the event of… Filing
  3. Sep 14, 2026AnnouncementThe Board of Directors of Vaxart, Inc., approved a Director Resignation Policy that requires a director, following certification of the stockholder vote from the meeting at which the election occurred, to promptly tender a written offer of resignation if the director receives more “withhold” votes… Filing
  4. Aug 25, 2026AnnouncementThe Board of Directors of Vaxart, Inc., upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee. Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jul 28, 2026AnnouncementUpon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. approved the reorganization of its Nominating and Governance Committee and the Compensation Committee, and the appointments of Kevin P. Finney as chair of the Nominating and Governance… Filing
  7. Jul 17, 2026VoteReported shareholder vote results. Filing
  8. Jul 7, 2026AnnouncementVaxart, Inc. announced topline 12-month safety data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Filing
  9. Jul 2, 2026AgreementVaxart, Inc. entered into a Cooperation Agreement with Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD, Patrice Raffy, Q3 Nominees Pty Ltd. and Marc Eustace Pereira. Filing
  10. Jun 26, 2026AgreementVaxart, Inc. entered into Modification No. 7 to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, with Advanced Technology International, the Rapid Response Partnership Vehicle’s Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority of the… Filing
  11. May 19, 2026AnnouncementVaxart, Inc. issued a letter to shareholders highlighting the Company’s clinical and operational progress, strategic priorities and commitment to long-term value creation and urging Vaxart shareholders to support the six director nominees nominated by the Company’s Board of Directors at the… Filing
  12. May 7, 2026ResultsReleased financial results. Filing
  13. Apr 23, 2026LeadershipFollowing a recommendation by the Nominating and Governance Committee of the Board of Directors of Vaxart, Inc., the Board appointed James B. Breitmeyer, M.D., Ph.D. to serve on the Board, effective immediately, and until Dr. Breitmeyer’s successor is elected and qualified, or sooner in the event… Filing
  14. Apr 21, 2026AnnouncementVaxart, Inc. entered into an amendment to its lease agreement with a landlord relating to certain properties currently leased to the Company that are located on Utah Avenue in South San Francisco, California. Filing
  15. Apr 17, 2026AgreementVaxart, Inc. entered into a purchase agreement and a registration rights agreement, with Lincoln Park Capital Fund, LLC, pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock, par value $0.0001 per share, subject to certain limitations and… Filing
  16. Mar 12, 2026ResultsReleased financial results. Filing
  17. Dec 29, 2025AgreementEnded an important agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vaxart financials

Questions about Vaxart, Inc. (VXRT) stock

Are VXRT insiders buying or selling?

In the last 12 months, VXRT insiders reported 5 open-market purchases worth $30.6K and no sales. The latest trade was on May 22, 2026. See every trade.

What is the short interest in VXRT?

As of Oct 30, 2026, 2.42M VXRT shares were sold short, 1.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 611,586 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.